Annual report pursuant to Section 13 and 15(d)

Goodwill and In-process R&D

v3.21.1
Goodwill and In-process R&D
12 Months Ended
Dec. 31, 2020
Goodwill and In-process R&D  
Goodwill and In-process R&D

7.        Goodwill and In-process R&D

Goodwill of $2.2 million and in-process R&D of $5.9 million were recorded in connection with the acquisition of Pelican, as described in Note 4. The Company performs an annual impairment test at the reporting unit level as of April 1st of each fiscal year. As of April 1, 2020, the Company qualitatively assessed whether it is more likely than not that the respective fair value of the reporting unit is less than its carrying amount, including goodwill. Based on that assessment, the Company determined that this condition does not exist. As such, performing the first step of the two-step test impairment test was unnecessary. No impairment was recorded during the year ended December  31, 2020.

 

However, during the year ended December 31, 2019, the Company experienced a sustained decline in the quoted market price of the Company’s common stock and as a result the Company determined that as of December 31, 2019 it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated fair value. Accordingly, the Company performed an interim impairment analysis as of that date using the income approach. This analysis required significant judgments, including primarily the estimation of future development costs, the probability of success in various phases of its development programs, potential post-launch cash flows and a risk-adjusted weighted average cost of capital. Pursuant to ASU 2017 04, the Company recorded a goodwill impairment charge for the excess of the reporting unit’s carrying value over its fair value. During the year ended December 31, 2019, goodwill with a total carrying value of $2.2 million was written down to its estimated fair value of $1.5 million and an impairment charge of $0.7 million was recorded.  

 

The following table provides the Company’s goodwill as of December 31, 2020. There was no goodwill impairment during the year ended December 31, 2020.

 

 

 

 

 

 

    

Goodwill

Balance at December 31, 2020

 

$

1,452,338

 

The following table provides the Company’s in-process R&D as of December 31, 2020. There was no change in in-process R&D during the years ended December 31, 2020 and 2019.

 

 

 

 

 

 

    

In-process

 

 

 R&D

In-process R&D from acquisition of Pelican

 

$

5,866,000

 

.